Cargando…

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santini, V, Allione, B, Zini, G, Gioia, D, Lunghi, M, Poloni, A, Cilloni, D, Sanna, A, Masiera, E, Ceccarelli, M, Abdel-Wahab, O, Terenzi, A, Angelucci, E, Finelli, C, Onida, F, Pelizzari, A, Ferrero, D, Saglio, G, Figueroa, M, Levis, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808077/ https://www.ncbi.nlm.nih.gov/pubmed/28607470 http://dx.doi.org/10.1038/leu.2017.186

Ejemplares similares

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis
por: Balleari, Enrico, et al.
Publicado: (2019)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report
por: Sheel, Ankur, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine: A case report
por: Jeon, So-Yeon, et al.
Publicado: (2023)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report
por: Liu, Huan, et al.
Publicado: (2018)

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study
por: Cilloni, Daniela, et al.
Publicado: (2020)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Novel splicing-factor mutations in juvenile myelomonocytic leukemia
por: Takita, J, et al.
Publicado: (2012)

Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report
por: Pelkey, Lauren J, et al.
Publicado: (2022)

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
por: Liu, Xiaoling, et al.
Publicado: (2012)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
por: DENG, QI, et al.
Publicado: (2015)

Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases
por: Volchkov, E. V., et al.
Publicado: (2023)

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
por: Gutierrez, Wade R., et al.
Publicado: (2022)

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
por: Galimberti, Sara, et al.
Publicado: (2012)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia
por: Hasegawa, D, et al.
Publicado: (2013)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
por: Lasho, T L, et al.
Publicado: (2015)

Endogenous and combination retinoids are active in myelomonocytic leukemias
por: di Martino, Orsola, et al.
Publicado: (2021)

Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression
por: Jensen, Holly A., et al.
Publicado: (2015)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_6n40pv1l3d56cc3vgh43d7tlj4